Cargando…
Exosome therapeutics for COVID‐19 and respiratory viruses
Respiratory viral diseases are a leading cause of mortality in humans. They have proven to drive pandemic risk due to their complex transmission factors and viral evolution. However, the slow production of effective antiviral drugs and vaccines allows for outbreaks of these diseases, emphasizing a c...
Autores principales: | Popowski, Kristen D., Dinh, Phuong‐Uyen C., George, Arianna, Lutz, Halle, Cheng, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995024/ https://www.ncbi.nlm.nih.gov/pubmed/34766162 http://dx.doi.org/10.1002/VIW.20200186 |
Ejemplares similares
-
Exosome therapeutics for lung regenerative medicine
por: Popowski, Kristen, et al.
Publicado: (2020) -
Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
por: Lutz, Halle, et al.
Publicado: (2021) -
Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung()
por: Popowski, Kristen D., et al.
Publicado: (2022) -
Dermal exosomes containing miR-218-5p promote hair regeneration by regulating β-catenin signaling
por: Hu, Shiqi, et al.
Publicado: (2020) -
Cell-Mimicking Nanodecoys Neutralize SARS-CoV-2 and Mitigate Lung Injury in a Nonhuman Primate Model of COVID-19
por: Li, Zhenhua, et al.
Publicado: (2021)